Related Experiment Video
Updated: Jun 10, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
An exact method for link parameter estimation in error benchmarking: an application to Phase II two-stage single arm
Christopher N Barnes1, Shesh N Rai
1Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky, USA. Chris.barnes@louisville.edu
Statistical Methods in Medical Research
|August 11, 2010
Summary
Bayesian trial designs can be improved by benchmarking against frequentist errors. A new method constructs a confidence prior for small-sample Phase II oncology trials, ensuring reliable Bayesian error assessment.
Area of Science:
- Clinical Trials
- Biostatistics
- Oncology
Background:
- Bayesian trial designs require a prior, which can be problematic in small Phase II oncology trials.
- Small sample sizes may not adequately inform or correct for an overly optimistic or misspecified prior.
- Comparing Bayesian and frequentist error metrics is crucial for trial validity.
Purpose of the Study:
- To address challenges in Bayesian trial design for small Phase II oncology studies.
- To introduce a method for constructing a confidence prior to equate Bayesian and frequentist errors.
- To ensure robust trial validity by benchmarking Bayesian errors with Type I and Type II error measures.
Main Methods:
- Development of an exact method for constructing a confidence prior.
- Modeling the small sample size characteristic of Phase II single-arm trials.
- Incorporation of the multi-stage decision process inherent in these trials.
Main Results:
- A novel method for creating a confidence prior is presented.
- This prior allows for the benchmarking of Bayesian errors against frequentist validity measures.
- The method accounts for the specific constraints of Phase II two-stage single-arm oncology trials.
Conclusions:
- The proposed exact method provides a reliable way to construct confidence priors for Bayesian trial designs.
- This approach enhances the validity and interpretability of Bayesian Phase II oncology trials.
- Clinicians can better assess treatment efficacy by equating Bayesian errors with frequentist benchmarks.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...